)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ProQR Therapeutics
ProQR Therapeutics (PRQR) investor relations material
ProQR Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
AX-0811 Phase 1 Cohorts 1 and 2 fully enrolled; initial target-engagement data expected in early Jan 2027, following positive AX-0810 Phase 1 target-engagement data reported in June 2026.
€103.0m cash and cash equivalents at Sep. 30, 2026, with runway expected into mid-2028.
Multiple pipeline milestones expected in H1 2027, including pediatric biliary atresia, AX-0422 in MPS I Hurler syndrome and AX-2911 for MASH.
Financial highlights
Q3 revenue €5.155m vs €2.882m YoY; 9M revenue €15.947m vs €11.218m.
Q3 R&D costs €14.323m vs €11.080m YoY; G&A costs €3.967m vs €3.119m.
Q3 net loss €12.447m vs €11.006m; 9M net loss €34.558m vs €33.264m.
Q3 net cash used in operating activities €13.586m vs €12.235m YoY; 9M cash used €37.001m vs €39.434m.
Outlook and guidance
Full AX-0810 Phase 1 dataset, including Cohort 3 and 12-week follow-up, and new AX-0811 preclinical data expected in Dec. 2026.
AX-0811 initial target-engagement data from healthy-volunteer Cohorts 1 and 2 expected in early Jan. 2027.
Pediatric biliary atresia IIT in China targeted for initiation and initial data in H1 2027; a potentially registration-enabling Phase 2 program is expected to start mid-2027, subject to regulatory interactions, with interim data by mid-2028.
AX-0422 CTA filing for a first-in-patient MPS I Hurler study anticipated in early 2027, with initial data in H1; AX-2911 MASH IIT in China expected in H1 2027.
Lilly collaboration continues; potential data updates and milestone payments anticipated.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ProQR Therapeutics
- AX-0810 validates human NTCP engagement as AX-0811 advances toward 2027 data.PRQR
Investor update - AX-0811 entered the clinic, with five trial readouts and major AI-driven advances expected this year.PRQR12th Annual Cantor Fitzgerald Global Healthcare Conference
- Positive AX-0810 Phase 1 data and $59.2M financing drive pipeline and extend cash runway to mid-2028.PRQRQ2 2026
- Registers 3,030,303 shares for resale by a shareholder; no proceeds to the company.PRQRRegistration filing
- AX-0810 and AX-0811 advance as potent, selective NTCP modulators with strong clinical momentum.PRQRConference presentation
- Clinical pipeline advances and AI partnerships drive progress, with cash runway into mid-2027.PRQRQ1 2026
- AI-driven RNA editing pipeline advances with major clinical milestones and partnerships ahead.PRQRStatus update
- Advanced clinical pipeline, strong cash position, and key data milestones expected in 2026.PRQRQ4 2025
- Lead RNA editing program in phase I, with major data and milestones expected in 2024.PRQRThe Citizens Life Sciences Conference 2026
Next ProQR Therapeutics earnings date
Q4 202612 Mar, 2027
ProQR Therapeutics
Next ProQR Therapeutics earnings date
Q4 202612 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ProQR Therapeutics N.V. is a biotechnology company focused on developing innovative RNA therapies for genetic diseases. Established in 2012 in Leiden, Netherlands, ProQR pioneers RNA editing technologies, specifically its proprietary platform called Axiomer. This technology enables precise RNA editing by using a cell's own ADAR enzymes to alter specific nucleotides in RNA molecules, potentially reversing mutations or modulating protein expression to address unmet medical needs in various diseases. The company's approach to drug development is particularly significant for conditions that currently lack effective treatments. Over the years, ProQR has expanded its pipeline beyond its initial focus on cystic fibrosis to include a range of rare and common diseases, with ongoing research and development efforts in fields such as inherited retinal diseases and liver diseases. The company is headquartered in Leiden, Netherlands, and its shares are listed on the NASDAQ.